AvenCell
Biotechnology ResearchMassachusetts, United States51-200 Employees
AvenCell is a Cambridge, Massachusetts-based biotechnology company with an estimated 51 to 200 employees. The company operates in biotechnology research and focuses on developing next-generation immunotherapies for hard-to-treat cancers, with revenue in the tens of millions and about $40 million in funding reported. AvenCell describes itself as a clinical-stage cell therapy company developing switchable CAR-T therapies for cancer. It maintains international operations, including AvenCell Europe GmbH and AvenCell Japan as subsidiaries. Its program pipeline includes AVC-201, a switchable allogeneic CAR-T candidate targeting CD123 for acute myeloid leukemia, and AVC-203, a dual-antigen (CD19 and CD20) allogeneic CAR-T therapy for B-cell lymphomas.
1-888-653-2347 
support@leadiq.com 
